Equities Analysts Offer Predictions for NKTR Q2 Earnings

Nektar Therapeutics (NASDAQ:NKTR - Free Report) - Equities research analysts at HC Wainwright reduced their Q2 2025 EPS estimates for shares of Nektar Therapeutics in a research report issued on Monday, May 12th. HC Wainwright analyst A. He now anticipates that the biopharmaceutical company will post earnings of ($0.18) per share for the quarter, down from their prior estimate of ($0.15). HC Wainwright has a "Buy" rating and a $6.50 price objective on the stock. The consensus estimate for Nektar Therapeutics' current full-year earnings is ($0.72) per share. HC Wainwright also issued estimates for Nektar Therapeutics' Q3 2025 earnings at ($0.17) EPS, FY2025 earnings at ($0.77) EPS and FY2026 earnings at ($0.84) EPS.

A number of other analysts also recently weighed in on the stock. Oppenheimer upgraded shares of Nektar Therapeutics from a "market perform" rating to an "outperform" rating and set a $6.00 target price on the stock in a report on Friday, March 14th. Jefferies Financial Group upgraded shares of Nektar Therapeutics from a "hold" rating to a "buy" rating and boosted their target price for the stock from $1.00 to $2.00 in a report on Friday, April 11th. William Blair restated a "market perform" rating on shares of Nektar Therapeutics in a report on Monday. Finally, StockNews.com began coverage on shares of Nektar Therapeutics in a report on Wednesday, April 16th. They issued a "hold" rating on the stock. Two investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Nektar Therapeutics presently has a consensus rating of "Moderate Buy" and a consensus price target of $4.50.

Nektar Therapeutics Stock Down 0.7%

Nektar Therapeutics stock opened at $0.71 on Wednesday. The company's 50-day moving average price is $0.70 and its 200-day moving average price is $0.90. Nektar Therapeutics has a twelve month low of $0.43 and a twelve month high of $1.86. The company has a market cap of $132.13 million, a PE ratio of -0.85 and a beta of 0.62.

Nektar Therapeutics (NASDAQ:NKTR - Get Free Report) last announced its quarterly earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.04). Nektar Therapeutics had a negative net margin of 180.70% and a negative return on equity of 173.28%. The company had revenue of $10.46 million during the quarter, compared to the consensus estimate of $15.61 million. During the same quarter in the prior year, the firm posted ($0.18) earnings per share.

Hedge Funds Weigh In On Nektar Therapeutics

Several hedge funds have recently added to or reduced their stakes in the company. Algert Global LLC bought a new position in Nektar Therapeutics during the 1st quarter valued at about $33,000. Nuveen LLC bought a new position in Nektar Therapeutics in the 1st quarter worth about $222,000. CM Management LLC grew its stake in Nektar Therapeutics by 6.7% in the 1st quarter. CM Management LLC now owns 800,000 shares of the biopharmaceutical company's stock worth $544,000 after acquiring an additional 50,000 shares in the last quarter. US Bancorp DE grew its stake in Nektar Therapeutics by 257.8% in the 1st quarter. US Bancorp DE now owns 50,085 shares of the biopharmaceutical company's stock worth $34,000 after acquiring an additional 36,085 shares in the last quarter. Finally, Deuterium Capital Management LLC bought a new position in Nektar Therapeutics in the 1st quarter worth about $381,000. 75.88% of the stock is currently owned by institutional investors.

About Nektar Therapeutics

Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.